Factor VIII (antihemophilic factor, AHF) is a plasma glycoprotein which in the purified state has a molecular weight of 1.12 X 106 (1). The partially purified protein has three distinct properties: (a) Factor VIII clot-promoting function (VIIIAHF), an activity which corrects the coagulation abnormality of plasma from a patient with classic hemophilia (hemophilia A); (b) Factor VIII antigen (VIIIAGN), an antigen identified in precipitin assays by heterologous antibodies and decreased in plasma of patients with von Willebrand's disease but normal in hemophilic plasma; and (c) von Willebrand factor (VIIIvwF), an activity deficient in von Willebrand's disease, which can be identified by an abnormality of the bleeding time or by in vitro assays of platelet function (ristocetin-induced aggregation and retention in glass bead columns). The term "Factor VIII" identifies a protein or proteins present in normal human plasma which is (are) responsible for these three activities. This operational nomenclature has recently been suggested by Weiss and coworkers (2) .
We recently have demonstrated that cultured human endothelial cells synthesize VIIIAGN though the protein does not have VIIIAHF activity (3) . In this paper we show the release of VIIIvwF by cultured endothelial cells.
MATERIALS AND METHODS
Endothelial Cells were obtained from human umbilical cord veins and cultured as previously described (4) . Post-culture medium was collected after 3 or 4 days of tissue culture, centrifuged at 25,000 X g for 30 min at 40, and then stored at -20°until needed.
Ristocetin Assay. VIIIVWF activity was initially assayed by the ristocetin method (2, 5, 6) . Washed normal human platelets were prepared using the Ardlie buffer system as previously described (7) . The buffer was modified by omitting calcium and adding 1 mM adenosine to all wash solutions and increasing the total number of washes to 5. The ristocetin assay was performed in a Chrono-Log aggregometer (Chrono-Log Corp.) using 0.2 ml of washed platelets (300,000/yl), 0.2 ml of the material to be tested, and ristocetin (Abbott Laboratories) at a final concentration of 1.5 mg/ml. Platelet aggregation was expressed as the percent change in light transmission 2 min after the addition of ristocetin.
Gel Chromatography. Culture media were concentrated by adding an equal volume of saturated ammonium sulfate, mixing for 1 hr at 200, incubating overnight at 40, centrifuging for 30 min at 25,000 X g at 40, and dissolving the precipitate in 1/20 of the original volume using phosphate-buffered saline (PBS, 0.145 M NaCl, 0.01 M phosphate, pH 7.4). This concentrate was then diluted 1:3 with PBS to reduce viscosity and samples of 10-15 ml were chromatographed on a 2.5 X 90-cm Sepharose 4B (Pharmacia Fine Chemicals) column. The separation was carried out in PBS at room temperature at an elution rate of 20 ml/hr and 6.9-ml fractions were collected. The column void volume was determined with Blue Dextran 2000 (Pharmacia). The fractions were assayed for VIIIvwF activity by the ristocetin assay and for VIIIAGN by radioimmunoassay (8) .
Glass Bead Retention. VIIIvwF activity was also assayed by the method of Bowie and coworkers (9) as modified by Coller and Zucker (10) with the following additional modifications: (1) commercially available glass bead columns holding 1.3 g of beads were used (Becton Dickinson), and (2) the first 3 ml of blood pumped through the column were discarded and the next 1 ml of blood was collected in 1/20 volume of 0.1 M ethylenediamine tetraacetic acid (EDTA) and the platelets counted. Fractions were tested by adding 6.3 ml of whole blood to syringes containing 0.7 ml of test fraction, mixing the contents of the syringe, incubating at room temperature for 15 min, and then pumping the blood through the glass bead columns at 6.1 ml/min. Void volume fractions derived from pre-and post-culture media were separately pooled and concentrated approximately 50-fold by ultrafiltration, using a PM-10 membrane (Amicon Corp.). Factor VIII concentrates were added to blood as Hemofil (Hyland Laboratories, 28 units/ml).
Antibodies to proteins synthesized by cultured human endothelial cells were prepared in rabbits as previously described (7) (12) using VIIIAHF-deficient human plasma (Dade) as substrate. Pooled normal human plasma (Hyland Laboratories) was used as the standard for these assays, and VIIIAHF values expressed as units/100 ml. One unit of VIIIAHF is defined as that activity corresponding to 1 ml of average normal human plasma (13) . The inhibition of VIIIAHF in human plasma by the rabbit anti-endothelial VIII was assayed after equal volumes of antibody and plasma were incubated for 2 hr at 37°. This mixture was then assayed for VIIIAIF and compared with a control in which normal rabbit serum was substituted for the rabbit anti-endothelial cell VIII.
RESULTS
Endothelial Cell VIIIVWF. Pre-and post-culture media were separately concentrated 4-fold by ultrafiltration and assayed for VIIIvwF activity by the ristocetin assay (Fig. 1) . Only the concentrated post-culture medium supported ristocetin-induced aggregation of washed normal human platelets.
The post-culture medium also contained VIIIvwF activity when assayed for the ability to correct the defect in platelet retention of blood from patients with von Willebrand's disease. Culture medium was concentrated and chromatographed on Sepharose 4B. The void volume fractions were added to blood from three patients with von Willebrand's disease ( Table 1 ). The concentrates from pre-culture medium had no consistent effect on platelet retention. In contrast, concentrates from post-culture media corrected the platelet retention defect to the same degree as did human Factor VIII concentrate prepared from pooled human plasma. In one patient (no. 3), the improvement in platelet adhesion to the glass beads was only partial following the addition of endothelial cell void volume material. This latter patient is unusual in that his endogenous levels of VIIIvwF are significantly higher than his plasma level of VIIIAHF (14) . Properties of Endothelial Cell VIIIlvw. When post-culture medium was concentrated by ammonium sulfate precipitation and chromatographed on Sepharose 4B, VIIIvwF and VIIIAGN activities appeared in an identical distribution (Fig. 2) Inhibition of Plasma VIIIVWF Activity by Rabbit AntiEndothelial Cell VIII. Antisera obtained by immunization with the concentrated void volume fraction significantly inhibited the platelet retention of normal blood in glass bead columns ( Table 2 ). The antibody reduced the platelet retention of normal blood to levels found in severe von Willebrand's disease (Table 1 ). This effect was related to the concentration of antibody and was abolished by addition of concentrated human Factor VIII ( Table 3) .
The Inhibitory Effect of Rabbit Anti-Endothelial Cell VIII on Plasma VIIIAHF Activity. Rabbit antiserum to endothelial cell VIII had minimal effect on the VIIIAHF activity of normal human plasma when the two were incubated for 2 hr at 37°. When equal volumes of undiluted antiserum and human plasma were used, the residual VIIIAHF activity was 44% of that of a control mixture in which normal rabbit serum was substituted for the antibody. This miiimal effect contrasts markedly with the ability of the rabbit anti-endothelial cell VIII to inhibit VIIIvwF activity in normal blood at a 1: 100 dilution.
Immunodiffusion Studies. On immunodiffusion analysis, rabbit anti-endothelial cell VIII and two rabbit antibodies to purified human Factor VIII (1, 8) reacted with a single line of identity when tested with a human Factor VIII preparation (Fig. 3) . The fetal-calf serum used in the culture medium did not form any precipitin lines when tested with a potent rabbit antibody to bovine Factor VIII (11) or with rabbit anti-human factor VIII (8). Although the anti-endothelial cell VIII showed a strong precipitin reaction against plasma VIIIAGN and was a strong inhibitor of plasma VIIIvwF activity, it was only a very weak inhibitor of plasma VIIIAHF activity. This dissociation has been previously observed in antisera from rabbits immunized with void volume concentrates derived from hemophilic plasma containing VIIIAGN and VIIIvwF activity but no detectable VIIIAHF activity (18) (19) (20) . Variability in VIIIAHF inactivating properties of rabbit antisera has also been observed for animals immunized with different preparations of purified normal human Factor VIII (21, 22) . The dissociation of reactivities in the rabbit anti-endothelial cell VIII corresponds to the dissociation of these properties in the endothelial cell culture medium. It is not yet clear why VIIIAHF has not been detected in media from cultured endothelial cells (3) . This may be due either to the lack of a necessary nutrient or precursor in the culture media, or to the functional heterogeneity of endothelial cells. Studies utilizing endothelial cells derived from adult veins and arteries cultured in a variety of different media may help clarify this problem. It is also possible that the endothelial cell VIIIAGNVIIIvwF complex serves as a precursor or carrier of VIIIAHF activity which develops due to interactions at a remote site, perhaps through contact with a second cell system or by modification by one or more plasma enzymes.
The demonstration that endothelial cells release and probably synthesize VIIIvwF, a factor which significantly influences normal platelet function, further substantiates the importance of platelet-endothelial cell interactions in normal hemostasis (23, 24) . Recent studies suggest that plasma VIIIvwF activity is present on the platelet surface (25) and interacts with a specific platelet membrane receptor which is absent or defective in the Bernard-Soulier syndrome (26) . It seems likely that circulating platelets normally adsorb VIIIvwF activity that has been synthesized by endothelial cells and which permits platelet interaction with damaged vessel surfaces. The nature of this physiologic interaction remains to be clarified.
